(7-thiocyanato-indan-4-yloxy)-acetic acid methyl ester | 779197-61-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (7-thiocyanato-indan-4-yloxy)-acetic acid methyl ester
• 英文别名: methyl 2-[(7-thiocyanato-2,3-dihydro-1H-inden-4-yl)oxy]acetate
• CAS: 779197-61-4
• 化学式: C₁₃H₁₃NO₃S
• 分子量: 263.317
• InChiKey: ANZMDPUOTMBEQF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  84.6
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (7-thiocyanato-indan-4-yloxy)-acetic acid methyl ester 在 bis-triphenylphosphine-palladium(II) chloride sodium hydroxide 、 copper(l) iodide 、 1,4-dithio-erythritol 、 TEA 、 sodium carbonate 作用下， 以 乙醇 、 水 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 10.5h， 生成 {7-[2-(3-morpholin-4-yl-prop-1-ynyl)-6-(4-trifluoromethylphenylethynyl)-pyridin-4-ylsulfanyl]-indan-4-yloxy}-acetic acid
  参考文献：
  名称：

  Design of a partial PPARδ agonist

  摘要：

  Structure based ligand design was used in order to design a partial agonist for the PPAR delta receptor. The maximum activation in the transactivation assay was reduced from 87% to 39%. The crystal structure of the ligand binding domain of the PPAR delta receptor in complex with compound 2 was determined in order to understand the structural changes which gave rise to the decrease in maximum activation. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.05.079
• 作为产物：
  描述：

  4-茚醇 在 溴 、 caesium carbonate 、 sodium bromide 作用下， 以 甲醇 、 乙腈 为溶剂， 生成 (7-thiocyanato-indan-4-yloxy)-acetic acid methyl ester
  参考文献：
  名称：

  Discovery of highly potent and selective benzyloxybenzyl-based peroxisome proliferator-activator receptor (PPAR) δ agonists

  摘要：

  A series of 1,4-benzyloxybenzylsulfanylaryl carboxylic acids were prepared and their activities for PPAR receptor subtypes (alpha, beta, and gamma) with potential indications for the treatment of dyslipidemia were investigated. Analog 13a displayed the greatest binding affinity (IC50 = 10 nM) and selectivity (120-fold) for PPAR delta over PPAR alpha. Many of the analogs investigated were found to be highly selective for PPAR delta and were dependent on the point of attachment of the substituent. In the 1,4-series, analog 28e was found to be the most potent (IC50 = 1.7 nM) and selective (> 1000-fold) compound for PPAR delta. None of the compounds tested showed appreciable binding affinity for PPAR gamma. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.04.046

文献信息

• Compounds that modulate PPAR activity and methods of preparation
  申请人：——

  公开号：US20040209936A1

  公开（公告）日：2004-10-21

  This invention relates to compounds that alter PPAR activity. The invention also relates to pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing dyslipidemia, hypercholesterolemia, obesity, hyperglycemia, atherosclerosis, hypertriglyceridemia and hyperinsulinemia in a mammal. The present invention also relates to methods for making the disclosed compounds.

  这项发明涉及改变PPAR活性的化合物。该发明还涉及这些化合物的药用盐、包含这些化合物或其盐的药用组合物，以及将它们用作治疗或预防哺乳动物中的脂质代谢异常、高胆固醇血症、肥胖、高血糖、动脉粥样硬化、高甘油三酯血症和高胰岛素血症的治疗剂的方法。本发明还涉及制备所述化合物的方法。
• COMPOUNDS THAT MODULATE PPAR ACTIVITY AND METHODS OF PREPARATION
  申请人：Warner-Lambert Company LLC

  公开号：EP1620086A1

  公开（公告）日：2006-02-01
• US6875780B2
  申请人：——

  公开号：US6875780B2

  公开（公告）日：2005-04-05
• US7244763B2
  申请人：——

  公开号：US7244763B2

  公开（公告）日：2007-07-17
• [EN] COMPOUNDS THAT MODULATE PPAR ACTIVITY AND METHODS OF PREPARATION<br/>[FR] COMPOSES MODULANT DES RECEPTEURS PPAR, ET LEURS PROCEDES DE PREPARATION
  申请人：WARNER LAMBERT CO

  公开号：WO2004091604A1

  公开（公告）日：2004-10-28

  This invention relates to compounds that alter PPAR activity. The invention also relates to pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing dyslipidemia, hypercholesterolemia, obesity, hyperglycemia, atherosclerosis, hypertriglyceridemia and hyperinsulinemia in a mammal. The present invention also relates to methods for making the disclosed compounds.